D
David Tamang
Publications - 28
Citations - 1194
David Tamang is an academic researcher. The author has contributed to research in topics: Bortezomib & Multiple myeloma. The author has an hindex of 11, co-authored 27 publications receiving 978 citations.
Papers
More filters
Journal ArticleDOI
Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma
Loredana Santo,Teru Hideshima,Andrew L. Kung,Jen-Chieh Tseng,David Tamang,Min Yang,Matthew Jarpe,John H. Van Duzer,Ralph Mazitschek,Walter Ogier,Diana Cirstea,Scott J. Rodig,Homare Eda,Tyler Scullen,Miriam Canavese,James E. Bradner,Kenneth C. Anderson,Simon S. Jones,Noopur Raje +18 more
TL;DR: In vivo and preclinical studies provide preclinical rationale for acetylated α-tubulin use as a pharmacodynamic biomarker in future clinical trials for HDAC6 inhibition in multiple myeloma.
Journal ArticleDOI
Ricolinostat, the First Selective Histone Deacetylase 6 Inhibitor, in Combination with Bortezomib and Dexamethasone for Relapsed or Refractory Multiple Myeloma
Dan T. Vogl,Noopur Raje,Sundar Jagannath,Paul G. Richardson,Parameswaran Hari,Robert Z. Orlowski,Jeffrey G. Supko,David Tamang,Min Yang,Simon S. Jones,Catherine Wheeler,Robert J Markelewicz,Sagar Lonial +12 more
TL;DR: At the recommended phase II dose of ricolinostat of 160 mg daily, the combination with bortezomib and dexamethasone is safe, well-tolerated, and active, suggesting that selective inhibition of HDAC6 is a promising approach to multiple myeloma therapy.
Journal ArticleDOI
Ricolinostat plus lenalidomide, and dexamethasone in relapsed or refractory multiple myeloma: a multicentre phase 1b trial
Andrew Yee,William I. Bensinger,Jeffrey G. Supko,Peter M. Voorhees,Jesus G. Berdeja,Paul G. Richardson,Edward N. Libby,Ellen E. Wallace,Nicole Birrer,Jill N. Burke,David Tamang,Min Yang,Simon S. Jones,Catherine Wheeler,Robert J Markelewicz,Noopur Raje +15 more
TL;DR: Preliminary evidence is provided that ricolinostat is a safe and well tolerated selective HDAC6 inhibitor, which might partner well with lenalidomide and dexamethasone to enhance their efficacy in relapsed or refractory multiple myeloma.
Journal ArticleDOI
Entinostat plus Pembrolizumab in Patients with Metastatic NSCLC Previously Treated with Anti-PD-(L)1 Therapy.
Matthew D. Hellmann,Pasi A. Jänne,Mateusz Opyrchal,Navid Hafez,Luis E. Raez,Dmitry I. Gabrilovich,Fang Wang,Jane B. Trepel,Min-Jung Lee,Akira Yuno,Sunmin Lee,Susan Brouwer,Serap Sankoh,Lei Wang,David Tamang,Emmett V. Schmidt,Michael L. Meyers,Suresh S. Ramalingam,Elaine Shum,Peter Ordentlich +19 more
TL;DR: In anti–PD-(L)1–experienced patients with NSCLC, entinostat plus pembrolizumab did not achieve the primary response rate endpoint but provided a clinically meaningful benefit, with objective response in 9% of patients.
Journal ArticleDOI
Enhancement of pomalidomide anti-tumor response with ACY-241, a selective HDAC6 inhibitor
TL;DR: Second generation selective HDAC6 inhibitor citarinostat (ACY-241), with a more favorable safety profile than non-selective pan-HDAC inhibitors, is shown to synergize with pomalidomide in in vitro and in vivo preclinical models, providing further impetus for clinical development of ACY-241 for use in combination with IMiDs for patients with multiple myeloma and potentially other B-cell malignancies.